Please read the DISCLAIMER at the bottom of the blog.

Rakesh Jhunjhunwala is considered to be the greatest investor in Indian Market. He is supposed to have made Rs 5000 crores by just investing Rs 5000 in Indian Stock Market. Rakesh Jhunjhunwala guru mantra to be successful in stock market is as enumerated below:

(a) He advises people to become interested in a stock when none is interested in the same stock. As per him BUY RIGHT & HOLD TIGHT for years to come. He has been holding few stocks for last 10 years and he is still minting money from those stocks.

(b) He further advises that one should not follow big investors blindly as their risk profile and long term goals with time frame may be difficult to be followed by retail investor.

(c) Market is supreme and every thing is reflected in the price and thus their is no point in fighting the trend as market is always right.

(d) One should be able to create a balance between the fear and greed.

(e) As per his words one has to learn the stock market trading as none can teach the market as stock market experience is the best teacher.

Thus follow Rakesh Jhunjhunwala advice in stock market, BE PATIENT and grow big like Warren Buffet or this iconic man from Dalaal Street.

If you subscribe to this blog with your email, you will get the post right in your INBOX moment it is posted on this blog. Do remember to activate the subscription in your email. GOOD LUCK.
There was an error in this gadget

Friday, November 21, 2008

Buy Lupin Labs: Prabhudas Lilladher ( LUPIN is a part of Rakesh Jhunjhunwala portfolio)


Ranjit Kapadia, Head – Research, PCG, Prabhudas Lilladher, is bullish on Lupin Labs. Here is how views the stock
( Rakesh Jhunjhunwala is holding LUPIN shares)

Ranjit Kapadia likes Lupin Labs
( LUPIN is in the portfolio of Rakesh Jhunjhunwala) and has advised to investors too look at it at this point. “Lupin has given consistent returns over the last three months and also over a one-year period,” he said. “However, in the last one month, the fall in the stock price was in line with the Sensex. But overall, the returns in the last three months and the last 12 months were far better than the Sensex,” he added.

As per Kapadia, the company has got a strong presence in the domestic market as well as the US and the Japanese market. “The US is its largest market. About 50% of the global pharma market is in the US, and Japan is the second largest market after the US. So, the company has a strong presence in all these three regions. The growth rates are much higher than the industry growth rates,” he said.

Kapadia said the company is doing exceedingly well in the domestic market. “They have grown by about 24% during the last quarter, and in the US market they have grown by about 85%, and in the Japanese market the growth rate was 24%. So, these excellent growth rates have taken the topline growth to 41% during the quarter. There was a margin improvement of 200 basis points from 17.1% to 19.1%, and the bottomline grew by about 53% during the quarter,” he said.

As per Sep 08 share holding pattern, Rakesh jhunjhunwala is holding 1,661,881 and 1,130,254 shares in the name of Jhunjhunwala Rakesh Radheshyam and Jhunjhunwala Rekha Rakesh respectively

No comments:

DISCLAIMER

DISCLAIMER: The author is not a registered stockbroker nor a registered advisor and does not give investment advice. His comments are an expression of opinion only and should not be construed in any manner whatsoever as recommendations to buy or sell a stock, option, future, bond, commodity, index or any other financial instrument at any time. While he believes his statements to be true, they always depend on the reliability of his own credible sources. The author recommends that you consult with a qualified investment advisor, one licensed by appropriate regulatory agencies in your legal jurisdiction, before making any investment decisions, and that you confirm the facts on your own before making important investment commitments.

Website hit counters